Logo of Skin Elements (ASX:SKN)Latest Skin Elements (ASX:SKN) News

Page 1
Page 1 of 2

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Skin Elements turns Farmlands deal into first New Zealand delivery as cash reaches A$1.455 million

Skin Elements has converted its New Zealand Farmlands agreement into a first NZ$150,000 ECO-Nurture delivery, while A$900,000 in placement proceeds lifted quarter-end cash to A$1.455 million. The commercial progress comes alongside a cost review and a regulatory hurdle still standing between the company and broader national sales.
Ada Torres
29 Oct 2026

Skin Elements lines up A$700,000 to push product portfolio forward

Skin Elements has secured firm commitments for a A$700,000 placement to fund working capital and commercialisation across its natural biotechnology portfolio. The raising includes 318.2 million free-attaching options, making shareholder approval and future dilution important next steps.
Ada Torres
27 Oct 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Skin Elements Locks NZ Deal, Raises $1.47M, and Overhauls Board

Skin Elements has secured an exclusive New Zealand distribution agreement for its ECO-Nurture bio-stimulant, raised $1.47 million through options and placement, and refreshed its board after shareholder votes.
Ada Torres
31 July 2026

Healthcare Wrap - Week 26 (22 June -> 26 June) 2026

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.
Logan Eniac
27 June 2026

Skin Elements Raises $900K at 25% Discount to Fuel Natural Biotech Pipeline

Skin Elements Limited has secured a $900,000 placement at a 25% discount to recent prices, bolstering its balance sheet to advance its natural biotechnology product range. The company also appointed Rod Nicholas as non-executive chairman and engaged Phoenix Global Investments for investor relations.
Ada Torres
26 June 2026

Healthcare Wrap - Week 23 (1 June -> 5 June) 2026

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.
Logan Eniac
6 June 2026

Takeovers Panel Ends Skin Elements Probe After 62 Capital Waives Transfer Restrictions

The Takeovers Panel has declined to investigate Skin Elements Limited's allegations of undisclosed investor associations following a $2.5 million placement, after 62 Capital agreed to waive transfer restrictions on placement securities.
Ada Torres
2 June 2026

Healthcare Wrap - Week 22 (25 May -> 29 May) 2026

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.
Logan Eniac
30 May 2026

Skin Elements Seeks Takeovers Panel Review Over Undisclosed Voting Association Ahead of Board Spill EGMs

Skin Elements Limited has lodged an application with the Takeovers Panel alleging undisclosed voting power exceeding 20% via a private placement, raising questions about shareholder rights ahead of critical board spill meetings.
Ada Torres
26 May 2026

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.
Logan Eniac
28 Feb 2026